IonQ reaches 1,000 patents milestone with new quantum computing grants
WESTMINSTER, CO—James Emmett Young, the Chief Financial Officer of TriSalus Life Sciences, Inc. (NASDAQ:TLSI), has acquired 6,000 shares of the company’s common stock, according to a recent filing with the Securities and Exchange Commission. The purchase, completed on February 5, 2025, was made at a price of $5.65 per share, totaling $33,900. The transaction comes as analysts maintain a strong buy consensus with price targets ranging from $10 to $16, according to InvestingPro data.
Following this acquisition, Young holds 30,000 shares indirectly through the Kathleen A. Young Living Trust, of which he is the sole trustee. Additionally, he directly owns 21,726 shares of TriSalus Life Sciences. The company, currently valued at $166 million, has demonstrated strong revenue growth of 68% in the last twelve months, though InvestingPro analysis indicates rapid cash burn remains a concern.
Investors often scrutinize insider transactions like these for potential insights into a company’s future performance. With TriSalus trading near its Fair Value based on InvestingPro metrics, subscribers can access 5 additional ProTips and comprehensive insider trading analysis tools to make more informed investment decisions.
In other recent news, TriSalus Life Sciences has reported a series of significant developments. The company announced a 59% annual revenue growth in 2024, reaching approximately $29.4 million, driven largely by its TriNav® Infusion System. A projection for revenue growth in excess of 50% for 2025 was also shared. Additionally, TriSalus has welcomed two new members to its Board of Directors, healthcare veterans William J. Valle and Dr. Gary B. Gordon. Their appointments are expected to provide strategic guidance to the company’s mission, leveraging their extensive experience in medical devices and oncology drug development. In a parallel move, the company reshuffled its executive team, appointing James Young as CFO, Dr. Richard Marshak as Chief Commercial Officer, and Jodi Devlin as Chief of Clinical Strategy and Operations. Canaccord Genuity, in response to the company’s Q3 report, has reduced its price target for TriSalus shares but maintained its Buy rating. These are all recent developments that continue to shape the trajectory of TriSalus Life Sciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.